[go: up one dir, main page]

ATE453669T1 - Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen - Google Patents

Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen

Info

Publication number
ATE453669T1
ATE453669T1 AT03726739T AT03726739T ATE453669T1 AT E453669 T1 ATE453669 T1 AT E453669T1 AT 03726739 T AT03726739 T AT 03726739T AT 03726739 T AT03726739 T AT 03726739T AT E453669 T1 ATE453669 T1 AT E453669T1
Authority
AT
Austria
Prior art keywords
fused
protein
ferritin
applications
polymeric
Prior art date
Application number
AT03726739T
Other languages
English (en)
Inventor
Daniel Carter
Chester Li
Original Assignee
New Century Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Century Pharmaceuticals filed Critical New Century Pharmaceuticals
Application granted granted Critical
Publication of ATE453669T1 publication Critical patent/ATE453669T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03726739T 2002-05-10 2003-05-12 Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen ATE453669T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37914502P 2002-05-10 2002-05-10
PCT/US2003/014617 WO2003094849A2 (en) 2002-05-10 2003-05-12 Ferritin fusion proteins for use in vaccines and other applications

Publications (1)

Publication Number Publication Date
ATE453669T1 true ATE453669T1 (de) 2010-01-15

Family

ID=29420496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726739T ATE453669T1 (de) 2002-05-10 2003-05-12 Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen

Country Status (8)

Country Link
US (2) US7097841B2 (de)
EP (1) EP1504037B1 (de)
CN (2) CN1659187A (de)
AT (1) ATE453669T1 (de)
AU (1) AU2003228962A1 (de)
CA (1) CA2485363C (de)
DE (1) DE60330767D1 (de)
WO (1) WO2003094849A2 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US9089521B2 (en) * 2001-11-01 2015-07-28 Robert H. Broyles Method for regulating production of hemoglobin beta chains
US8084017B2 (en) * 2002-03-07 2011-12-27 Carnegie Mellon University Contrast agents for magnetic resonance imaging and methods related thereto
US7998704B2 (en) * 2002-03-07 2011-08-16 Carnegie Mellon University Methods for magnetic resonance imaging
CA2485363C (en) * 2002-05-10 2014-10-28 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
ES2293243T3 (es) * 2003-04-02 2008-03-16 Turun Yliopisto Nanoparticula para ensayos de bioafinidad.
FI20030615A0 (fi) * 2003-04-24 2003-04-24 Marko Virta Nanopartikkeli bioaffiniteettimäärityksiin
CA2588871A1 (en) * 2004-12-02 2006-07-13 Csir Gram positive bacterial cells comprising a disrupted flagellin gene, flagellin-based fusion proteins and use in removal of metal ions from a liquid
AU2006276083B2 (en) * 2005-07-26 2012-04-19 Cms Peptides Patent Holding Company Limited Novel biologically active peptides and their new uses
ATE491022T1 (de) * 2005-10-18 2010-12-15 Nat Jewish Health Konditionell immortalisierte adulte langzeit- stammzellen und verfahren zur herstellung und verwendung von solchen zellen
KR100772491B1 (ko) 2005-10-31 2007-11-01 고려대학교 산학협력단 ＤｎａＫ와 고친화력을 가지는 모티브를 포함하는 주형단백질과 탐침 단백질이 융합된 단백질 나노입자
GB0621894D0 (en) 2006-11-02 2006-12-13 Iti Scotland Ltd Magnetic recognition system
WO2008067591A1 (en) * 2006-12-04 2008-06-12 Innovative Purification Technologies Pty Ltd Protein particles
WO2008124483A1 (en) * 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics
EP2285832B1 (de) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antikörper und herstellungsverfahren dafür
ES2681478T3 (es) 2008-08-28 2018-09-13 Taiga Biotechnologies, Inc. Moduladores de MYC, métodos de uso de los mismos y métodos para identificar agentes que modulan MYC
WO2011050168A2 (en) 2009-10-21 2011-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Rsv immunogens, antibodies and compositions thereof
CN102115746B (zh) * 2009-12-30 2013-06-05 中国科学院地质与地球物理研究所 一种单分散性磁性人铁蛋白的制备方法
US9241986B2 (en) 2010-01-04 2016-01-26 Kj Biosciences Llc DPS fusion proteins for use in vaccines and diagnostics
CA2813752A1 (en) 2010-10-06 2012-04-12 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
US9441019B2 (en) 2011-09-23 2016-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza hemagglutinin protein-based vaccines
EP3456731A1 (de) * 2011-09-30 2019-03-20 Korea University Research and Business Foundation, Sejong Campus Peptid zur synthese von kieselsäure und verwendung davon
WO2013055058A2 (ko) * 2011-10-12 2013-04-18 한국생명공학연구원 항체결합 펩타이드-페리틴 융합단백질 및 이의 용도
EP2834263B9 (de) 2012-04-05 2019-02-27 University Of Washington Through Its Center For Commercialization Epitope-scaffold immunogenische peptide gegen rsv
US20150098966A1 (en) 2012-05-16 2015-04-09 Kj Biosciences Llc Influenza vaccines
ES2856179T3 (es) 2012-07-20 2021-09-27 Taiga Biotechnologies Inc Reconstitución y autorreconstitución potenciadas del compartimento hematopoyético
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
EP3054971B1 (de) * 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr-virus-impfstoffe
KR101612095B1 (ko) * 2014-01-16 2016-04-26 한국과학기술연구원 바이오마커의 조기 검출 및 정밀 정량화가 가능한 바이오마커 탐지용 프로브 및 이의 용도
CA2950085A1 (en) 2014-05-27 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
WO2016048246A1 (en) * 2014-09-25 2016-03-31 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
CN105801706B (zh) * 2014-12-31 2019-10-22 深圳先进技术研究院 蝎氯毒素多肽-铁蛋白重链融合蛋白、自组装蛋白质纳米笼及其制备方法和应用
EP3250233A4 (de) 2015-01-29 2018-07-25 Agency for Science, Technology and Research Nanokapseln mit chikungunya-assoziierten peptiden
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
KR101888675B1 (ko) * 2015-09-02 2018-08-14 경북대학교 산학협력단 인간 유래 페리틴 모노머 단편 및 이를 이용한 융합폴리펩티드
WO2017066484A2 (en) * 2015-10-13 2017-04-20 Carter Daniel C Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
AU2016362597C1 (en) * 2015-12-04 2022-05-26 Dana-Farber Cancer Institute, Inc. Vaccination with MICA/B alpha 3 domain for the treatment of cancer
CN107344969B (zh) * 2016-05-05 2021-03-05 中国科学院武汉病毒研究所 一种纳米流感疫苗及构建方法和应用
EP3474893A1 (de) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Selbstorganisierende insektenferritin-nanopartikel zur darstellung von co-assemblierten trimeren antigenen
CN106046177B (zh) * 2016-08-19 2020-02-21 北华大学 P-5m-Fc融合蛋白及其表达基因、制备方法和应用
EP3506938A1 (de) 2016-09-02 2019-07-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Stabilisierte influenza-hämagglutininstammregiontrimere der gruppe 2 und verwendungen davon
WO2018102678A1 (en) 2016-12-02 2018-06-07 Taiga Biotechnologies, Inc. Nanoparticle formulations
US11261236B2 (en) 2017-01-06 2022-03-01 Kyungpook National University Industry-Academic Cooperation Foundation Fusion peptide comprising thrombus-targeting peptide, ferritin fragment and thrombolytic peptide, and use thereof
US10538756B2 (en) 2017-03-06 2020-01-21 The Trustees Of Princeton University Disordered protein-based seeds for molecular clustering
CN108976299B (zh) * 2017-06-05 2020-02-14 昆山新蕴达生物科技有限公司 一种改善抗体片段亲和力和体内半衰期的方法
CN107325176B (zh) * 2017-06-16 2020-12-25 神威药业集团有限公司 源于血红蛋白的免疫活性人胎盘多肽
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
WO2019195276A1 (en) * 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
MX2020010199A (es) 2018-04-03 2021-01-08 Sanofi Sa Polipeptidos antigenicos del virus sincitial respiratorio.
EP3773708A2 (de) 2018-04-03 2021-02-17 Sanofi Antigene epstein-barr-virus-polypeptide
JP2021519596A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
EP3801601A4 (de) * 2018-06-05 2022-09-28 International AIDS Vaccine Initiative Ferritin-nanopartikel, die ein hiv-trimer aufweisen
WO2020047263A2 (en) 2018-08-29 2020-03-05 Fred Hutchinson Cancer Research Center Sequential immunization strategies to guide the maturation of antibodies against human immmunodeficiency virus
CN109966483B (zh) * 2019-04-08 2021-07-30 中国科学院过程工程研究所 一种基于铁蛋白的多抗原通用流感疫苗及其制备方法和应用
AU2020272664A1 (en) 2019-04-08 2021-11-04 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
JP7391997B2 (ja) * 2019-04-25 2023-12-05 アグリカルチュラル テクノロジー リサーチ インスティテュート 豚熱ウイルス感染を予防するための組換えタンパク質、それを含む組成物及び細胞
TWI776048B (zh) * 2019-04-25 2022-09-01 財團法人農業科技研究院 預防豬瘟病毒感染之重組蛋白質及含其之組合物及細胞
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion
WO2020243895A1 (zh) * 2019-06-04 2020-12-10 上海鑫湾生物科技有限公司 促进毛发生长和/或再生的疫苗、其制备方法及其应用
EP4007779A4 (de) * 2019-08-01 2023-09-06 The Hospital for Sick Children Multivalente und multispezifische nanopartikelplattformen und verfahren
CN110478480B (zh) * 2019-08-22 2022-06-24 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 基于铁蛋白纳米颗粒的羊口疮f1l疫苗及其制备方法
WO2021045210A1 (ja) * 2019-09-05 2021-03-11 味の素株式会社 ペプチド内包フェリチン
CN110898219B (zh) * 2019-12-11 2022-01-14 中国科学院生物物理研究所 基于铁蛋白与preS1抗原基因融合表达的疫苗
CN111603555B (zh) * 2020-03-23 2022-10-21 东北农业大学 一种自组装牛副流感病毒3型纳米颗粒样抗原及其应用
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
JP2023550895A (ja) * 2020-10-30 2023-12-06 セレメディー カンパニー，リミテッド 抗体様タンパク質およびその用途
CN112342207B (zh) * 2020-11-27 2022-09-30 华侨大学 一种低速离心纯化重组木聚糖酶的方法
US20230054648A1 (en) * 2021-05-03 2023-02-23 Agilent Technologies, Inc. Chimeric immunogens and methods for making polyclonal antibodies against specific epitopes
WO2025076013A1 (en) 2023-10-01 2025-04-10 Vaccine Company, Inc. Engineered middle east respiratory syndrome proteins and related methods
WO2025077347A1 (zh) * 2023-10-13 2025-04-17 江南大学 多聚融合蛋白纳米载体及其应用
WO2025224710A1 (en) 2024-04-26 2025-10-30 Vaccine Company, Inc. Engineered orthopoxvirus proteins and related methods
CN119320460B (zh) * 2024-12-17 2025-03-14 中国农业科学院生物技术研究所 Bst DNA聚合酶和铁蛋白的融合蛋白及其突变体和应用
CN120757667A (zh) * 2025-09-02 2025-10-10 中国农业科学院生物技术研究所 自组装铁蛋白纳米抗原颗粒及其在制备鸭甲型肝炎疫苗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
AU641936B2 (en) * 1989-08-18 1993-10-07 Monsanto Company Ferritin analogs
US5248589A (en) * 1991-02-21 1993-09-28 Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Separation of cells and biological macromolecules by ferritin conjugates
EP0956046A4 (de) * 1996-06-12 2004-10-20 Yajun Guo Zelluläre impfstoffe und immuntherapeutika sowie verfahren zu deren herstellung
CA2485363C (en) * 2002-05-10 2014-10-28 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications

Also Published As

Publication number Publication date
AU2003228962A1 (en) 2003-11-11
EP1504037B1 (de) 2009-12-30
CA2485363C (en) 2014-10-28
CN105566497A (zh) 2016-05-11
CN1659187A (zh) 2005-08-24
US20040006001A1 (en) 2004-01-08
AU2003228962A8 (en) 2003-11-11
WO2003094849A2 (en) 2003-11-20
WO2003094849A3 (en) 2004-04-15
US7608268B2 (en) 2009-10-27
CA2485363A1 (en) 2003-11-20
EP1504037A2 (de) 2005-02-09
EP1504037A4 (de) 2005-06-08
US20060251679A1 (en) 2006-11-09
US7097841B2 (en) 2006-08-29
DE60330767D1 (de) 2010-02-11

Similar Documents

Publication Publication Date Title
ATE453669T1 (de) Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen
ATE360031T1 (de) Chimäre proteine und anwendungen
JP2019013251A5 (de)
MX2020010466A (es) Vectores de virus que evitan anticuerpos.
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
EE200200538A (et) Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
DE60325892D1 (de) Stellungs- und verwendungsverfahren
DK1767546T3 (da) Angiogenese-inhiberende kimært protein og dets anvendelse
UA90657C2 (ru) Ловушки vegf и их терапевтические применения
ATE350049T1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
MX2009011638A (es) Composiciones basadas en gp5 de prrsv y metodos.
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
DE60335726D1 (de) Chromoprotein und fluoroproteine
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
EA200501711A1 (ru) Семейство секретируемых белков
DE602004007924D1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
MXPA05009954A (es) Familia de proteinas secretadas.
GB0409559D0 (en) Polypeptide
DK1569961T3 (da) Splice variant af det menneskelige hypofysevæksthormon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties